Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole

Inclusion Criteria:

• Subjects must have histologically confirmed, locally advanced or metastatic solidcancers of the following histological types:

1. predominantly epithelial (≥50% tumor component) pleural or peritonealmesothelioma

2. epithelial ovarian cancer (fallopian tube and primary peritoneal cancers areeligible)

3. adenocarcinoma of the pancreas,

4. triple-negative adenocarcinoma of the breast

5. non-small-cell adenocarcinoma of the lung

6. gastric cancer (including gastro-esophageal junction)

7. colon cancer

8. cholangiocarcinoma

9. Thymic carcinoma

• Subjects must have no standard therapy available, or have actively refused standardtherapy

• Subjects must provide samples of archival tumor tissue collected and submitted anytimeduring the study

• Subjects must have a life expectancy of at least 12 weeks

• Subjects must have ECOG (Eastern Cooperative Oncology Group) performance status of 0or 1

• Subjects must have adequate bone marrow, renal and hepatic function and coagulation

• Subjects must have normal or clinically insignificant ECG at screening

• Women of reproductive potential must have a negative serum pregnancy test obtainedwithin 3 days before the start of anetumab ravtansine

• Women of childbearing potential and fertile men must agree to use adequatecontraception when sexually active. This applies from the time period between signingof the informed consent until at least 6 months after the last administration of thelast study drug. Male patients with a female partner of childbearing potential mustuse a condom and ensure that an additional form of contraception is also used duringtreatment and until 6 months after last study drug administration.

Exclusion Criteria:

• Previous or concurrent cancer that is distinct in primary site or histology from thecancer being evaluated in this study, except cervical carcinoma in situ, treated basalcell carcinoma, superficial noninvasive bladder tumors or any previous cancercuratively treated ≥ 3 years before the start of anetumab ravtansine

• New or progressive brain or meningeal or spinal metastases

• Corneal epitheliopathy or any eye disorder that may predispose the subjects todrug-induced corneal epitheliopathy, or may interfere with diagnosis oftreatment-emergent corneal epitheliopathy at the ophthalmologist's or theinvestigator's discretion

• History or current evidence of

• biliary cirrhosis

• malignant biliary obstruction unless the bile flow to the gastrointestinal tractis maintained by a fully operational biliary stent

• CTCAE (Common Terminology Criteria for Adverse Events) Grade ≥2 bleeding disorderwithin 4 weeks before the start of anetumab ravtansine

• uncontrolled cardiovascular disease or uncontrolled hypertension

• Long QT Syndrome

• HIV infection

• Hepatitis B or C infection

• Had a major surgery or significant trauma within 4 weeks before the start of anetumabravtansine

• Had solid organ or bone marrow transplantation

• Have LVEF (left ventricular ejection fraction) <50% at screening

• Have QTc >450 ms or heart rate ≥100 bpm or ≤45 bpm at screening

• Poor CYP2D6 metabolizers based on the screening test for genetic polymorphisms inCYP2D6 metabolizing capacity